DoMore Diagnostics and Proscia partner to inform personalized treatment decisions for colorectal cancer patients

Sept. 5, 2023
Collaboration holds the promise to reduce overtreatment with integrated AI-powered pathology workflows.

DoMore Diagnostics and Proscia have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients. The collaboration paves the way for integrating artificial intelligence (AI)-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.

The partnership paves the way for delivering an integrated solution that combines DoMore Diagnostics’ CE-IVDD marked Histotype Px Colorectal digital biomarker with Proscia’s CE-IVDR marked Concentriq Dx enterprise pathology platform. Data previously published in The Lancet and Lancet Oncology demonstrated that Histotype Px Colorectal can successfully predict outcomes for stage II and stage III CRC patients. Combined with tumor and lymph node status, the test report provides information about patients’ risk profile and 5-year cancer-specific survival to inform the decision to use adjuvant chemotherapy.

Concentriq Dx is an enterprise pathology platform that drives primary diagnostic workflows for reference laboratories, hospitals, and health systems of all sizes. It allows pathologists to quickly transition away from the microscope and work with speed and ease. An open platform, Concentriq Dx is designed to integrate AI applications from Proscia, Proscia’s customers, and leading third parties, including DoMore Diagnostics, into routine workflows so that laboratories can realize the full promise of pathology’s computational future at scale.

Proscia release